1-2 of 2
William Wilson
Close
Sort by
Journal Articles

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Clinical Trials & Observations
Michael Northend, William Wilson, Wendy Osborne, Christopher P. Fox, Andrew J. Davies, Dima El-Sharkawi, Elizabeth H. Phillips, Hau Wui Sim, Shalal Sadullah, Nimish Shah, Ying Ying Peng, Iman Qureshi, Juanah Addada, Rocio Figueroa Mora, Neil Phillips, Andrea Kuhnl, Elizabeth Davies, David Wrench, Pamela McKay, Indrani Karpha, Anna Cowley, Richard Karim, Sarah Challenor, Vikram Singh, Cathy Burton, Rebecca Auer, Chris Williams, Joel Cunningham, Angus Broom, Anita Arasaretnam, Claire Roddie, Tobias Menne, William Townsend
Journal: Blood Advances
Blood Adv (2022) 6 (9): 2920–2926.
https://doi.org/10.1182/bloodadvances.2021005953
Published: 2022
Includes: Supplemental data
Journal Articles

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP

Clinical Trials & Observations
Toby A. Eyre, William Wilson, Amy A. Kirkwood, Julia Wolf, Catherine Hildyard, Hannah Plaschkes, John Griffith, Paul Fields, Arief Gunawan, Rebecca Oliver, Stephen Booth, Jaimal Kothari, Christopher P. Fox, Nicolas Martinez-Calle, Andrew McMillan, Mark Bishton, Graham P. Collins, Chris S. R. Hatton
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2229–2236.
https://doi.org/10.1182/bloodadvances.2021004286
Published: 2021
Includes: Supplemental data